M. Shimizusasamata et al., YM90K - PHARMACOLOGICAL CHARACTERIZATION AS A SELECTIVE AND POTENT PHA-AMINO-3-HYDROXY-5-METHYLISOXAZOLE-4-PROPIONATE KAINATE RECEPTOR ANTAGONIST, The Journal of pharmacology and experimental therapeutics, 276(1), 1996, pp. 84-92
We investigated the pharmacological properties and neuroprotective act
ions of a novel pha-amino-3-hydroxy-5-methylisoxazole-y-propionate (AM
PA)/kainate receptor antagonist, midazol-1-yl)-7-nitro-2,3-(1H,4H)-qui
noxalinedione hydrochloride (YM90K); formerly YM900], in comparison wi
th those of -dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX).
YM90K selectively displaced [H-3]-AMPA binding (Ki = 0.084 mu M) and
was less potent in inhibiting [H-3]-kainate (Ki = 2.2 mu M), [H-3]-L-g
lutamate (N-methyl-D-aspartate-sensitive site; Ki > 100 mu M) and [H-3
]-glycine (strychninine-insensitive site; Ki = 37 mu M) binding to rat
brain membranes. YM90K co-injected with AMPA or kainate into the rat
striatum protected cholinergic neurons against AMPA- or kainate-induce
d neurotoxicity. YM90K showed potent suppressive activity against audi
ogenic seizure in DBA/2 mice; ED(50) values of YM90K and NBQX against
tonic seizure were 2.54 and 7.17 mg/kg (i.p.), respectively. The durat
ion of the anticonvulsant effects of YM90K and NBQX was 30 min, indica
ting that both compounds possess short action. In a global ischemia mo
del, YM90K (15 mg/kg i.p. x 3), NBQX (30 mg/kg i.p. x 3) and CNQX (60
mg/kg i.p. x 3) significantly prevented the delayed neuronal death in
the hippocampal CA1 region in Mongolian gerbils when administered 1 h
after 5-min ischemia. In addition, the therapeutic time window for the
neuroprotective effect of YM90K (30 mg/kg i.p. x 3) was 5 h. In a foc
al ischemia model, YM90K (30 mg/kg i.v. bolus + 10 mg/kg/h for 4 h) re
duced the volume of ischemic damage in the cerebral cortex in F344 rat
s. Thus, YM90K was shown to be a potent and selective antagonist for A
MPA/kainate receptors in vitro and in vivo. This compound may provide
a therapeutic effect in various neurodegenerative disorders such as is
chemic stroke in which glutamate neurotoxicity is thought to play a cr
itical role in neuronal damage.